ANVISA approval for the Spectrila® marketing authorization transfer enables SteinCares to ensure uninterrupted access to essential Acute Lymphoblastic Leukemia (ALL) treatment in Brazil. The milestone strengthens SteinCares’ onco-hematology portfolio and...
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform Collaboration aims to expand patient access to cost-effective treatments and reinforces SteinCares’ leadership in biosimilars...
San Jose, Costa Rica, January 19th, 2026 — SteinCares announced today that Moody’s Investors Service has assigned the company an AA credit rating with Stable outlook, highlighting its solid financial position, resilient business model, and disciplined operational...
SteinCares strengthens its role as the regional partner for global pharmaceutical companies seeking to bring innovative therapies to Latin American patients. Through this agreement, the company will continue to expand access to innovative, high-quality, and...
The new facility will enable the packaging and distribution of innovative medicines from Costa Rica to the entire Latin American region. This strategic investment reinforces SteinCares’ commitment to sustainable growth and job opportunties for the region. San Jose,...
SteinCares enters Mexico—one of the most strategic pharmaceutical markets in Latin America—to expand its footprint and accelerate growth across the region. The partnership marks a major milestone in SteinCares’ regional expansion, underscoring its commitment to...
